Recent studies demonstrated that YKL-5-124, a novel covalent CDK7 inhibitor, combined with JQ1, induced synergistic cytotoxicity in vitro and significant tumor regression in patient-derived xenograft neuroblastoma models (115). Here, CDK7 is linked to neuroblastoma.